What Is Spyre Therapeutics, Inc. (SYRE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Spyre Therapeutics, Inc.'s intrinsic value is estimated at $18.84, suggesting the stock is overvalued at its current price of $102.07. With 12 out of 12 models flagging downside (-81.5% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $85.01 (-16.7%), versus Sentiment SOTP at $1.14 (-98.9%). This +82.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About SYRE?
12 of 13 models are currently active for SYRE. All 12 active models suggest the stock trades above fair value. The Bayesian DCF estimates SYRE's intrinsic value at $12.15, implying -88.1% downside from the current price. See which stocks rank higher →
How Does SYRE Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SYRE ranks #257 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Spyre Therapeutics, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is SYRE a Value Trap?
CirclFi's Value Trap algorithm assigns SYRE a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Spyre Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Spyre Therapeutics, Inc. is rated at 4.6/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +82.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SYRE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SYRE's 12 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad